Skip to main content

Table 3 Adjusted odds ratios for treatment of female breast cancers (1st 12 months from diagnosis) by country of birth; New South Wales 2003–2016a

From: Female breast cancer in New South Wales, Australia, by country of birth: implications for health-service delivery

Predictor

Total number cases (n = 46,779)

aOR Any treatment (n = 46,297)

aOR Surgery (n = 43,653)

aOR Mastectomy (n = 18,283)

aOR Conserving surgery (n = 25,327)

aOR Radiotherapy (n = 31,132)

aOR Systemic therapy (n = 39,231)

Country of birth

Australia (n = 30,344)

1.000

1.000

1.000

1.000

1.000

1.000

China (mainland) (n = 1045)

0.463 (0.257,0,835)

1.021 (0.744,1.401)

1.625 (1.430,1.846)

0.605 (0.531,0.689)

0.610 (0.535,0.695)

0.715 (0.605,0.845)

Germany (n = 430)

0.795 (0.315,2.004)

0.835 (0.554,1.258)

0.838 (0.683,1.028)

1.146 (0.935,1.405)

1.134 (0.916,1.404)

0.683 (0.535,0.871)

Greece (n = 502)

0.885 (0.398,1.965)

0.792 (0.553,1.132)

0.757 (0.624,0.917)

1.254 (1.073,1.516)

1.313 (1.076,1.603)

0.984 (0.768,1.260)

Italy (n = 733)

2.279 (0.897,5.793)

1.059 (0.766,1.465)

0.734 (0.626,0.861)

1.403 (1.198,1.644)

1.431 (1.210,1.692)

1.153 (0.933,1.425)

Lebanon (n = 591)

2.399 (0.579,9.935)

1.116 (0.750,1.660)

0.614 (0.512,0.737)

1.666 (1.393,1.994)

1.518 (1.242,1.857)

1.034 (0.802,1.333)

New Zealand (n = 1005)

0.484 (0.262,0.892)

0.854 (0.634,1.151)

1.066 (0.934,1.217)

0.918 (0.804,1.048)

0.938 (0.815,1.080)

0.961 (0.798,1.156)

Philippines (n = 767)

1.026 (0.373,2.824)

1.254 (0.846,1.858)

1.477 (1.273,1.714)

0.693 (0.596,0.807)

0.646 (0.555,0.752)

1.009 (0.811,1.256)

United Kingdom (n = 3299)

0.917 (0.633,1.328)

0.929 (0.787,1.097)

0.911 (0.844,0.984)

1.080 (1.001,1.167)

1.130 (1.042,1.226)

0.986 (0.892,1.091)

Vietnam (n = 482)

1.327 (0.315,5.593)

1.178 (0.709,1.955)

1.542 (1.278,1.859)

0.643 (0.532,0.778)

0.646 (0.534,0.781)

0.903 (0.695,1.174)

Other mainly English speaking (n = 838)

0.827 (0.370,1.851)

1.125 (0.789,1.605)

1.130 (0.978,1.305)

0.893 (0.772,1.033)

0.948 (0.812,1.107)

0.845 (0.696,1.027)

Other mainly non-English speaking (n = 6743)

0.491 (0.385,0.627)

0.750 (0.667,0.843)

0.958 (0.906,1.014)

0.984 (0.930,1.041)

0.953 (0.899,1.011)

0.801 (0.745,0.863)

Age at diagnosis (18 + years)

Continuous (n = 46,779)

0.913 (0.903,0.923)

0.932 (0.926,0.937)

1.013 (1.010,1.017)

0.965 (0.962,0.968)

0.911 (0.908,0.915)

0.942 (0.938,0.945)

SEIFA SES Disadvantage

1 (most) (ref.) (n = 8346)

1.000

1.000

1.000

1.000

1.000

1.000

2 (n = 8591)

0.983 (0.754,1.281)

1.157 (1.016,1.317)

0.962 (0.903,1.026)

1.080 (1.012,1.152)

1.081 (1.012,1.155)

1.007 (0.926,1.095)

3 (n = 8847)

1.229 (0.919,1.645)

1.249 (1.094,1.427)

0.967 (0.908,1.031)

1.096 (1.028,1.168)

1.121 (1.049,1.198)

1.050 (0.965,1.141)

4 (n = 9751)

1.370 (1.018, 1.844)

1.176 (1.032,1.340)

0.926 (0.870,0.985)

1.127 (1.058,1.200)

1.222 (1.145,1.305)

1.132 (1.041,1.230)

5 (least) (n = 11,244)

2.068 (1.480,2.889)

1.484 (1.296,1.700)

0.928 (0.891,1.012)

1.158 (1.090,1.232)

1.309 (1.228,1.396)

1.153 (1.063,1.251)

Year of diagnosis

Continuous (2003 to 2016) (n = 46,779)

0.995 (0.991,1.000)

0.982 (0.971,0.992)

0.981 (0.976,0.985)

1.015 (1.010,1.020)

0.644 (0.595,0.698)

1.054 (1.047,1.061)

Stage (degree of spread)

Local (ref.) (n = 25,149)

1.000

1.000

1.000

1.000

1.000

1.000

Regional (n = 18,512)

0.806 (0.610,1.065)

0.732 (0.660,0.813)

2.809 (2.699,2.923)

0.342 (0.329,0.356)

1.355 (1.298,1.414)

4.277 (4.007,4.565)

Distant (n = 3118)

0.058 (0.046,0.073)

0.030 (0.027,0.033)

1.010 (0.931,1.097)

0.114 (0.103,0.125)

0.644 (0.595,0.698)

2.356 (2.111,2.631)

Comorbidity Index (Charlson)

0 (ref.) (n = 45,486)

1.000

1.000

1.000

1.000

1.000

1.000

 

> 0 (n = 1293)

0.246 (0.191,0.317)

0.314 (0.266,0.371)

0.874 (0.774,0.986)

0.632 (0.558,0.717)

0.472 (0.416,0.535)

0.680 (0.595,0.778)

  1. a(95% confidence limits); adjusted for age at diagnosis, SES, year of diagnosis, stage and comorbidity index; Multivariate logistic regression (see text) Excludes multiple primary cancers and local health districts bordering other states/territories (see text). Treatment data for women with a recorded stage; numbers receiving specified treatment in brackets under column headings
  2. aOR adjusted odds ratio, SEIFA SES socio-economic indexes for areas, ref reference